This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients accrued
Patients with multiple myeloma
Number of approved sites
Biobank participants
Paper on the second revision of the International Staging System (R2-ISS) accepted for publication!
Read moreThe MRDR was recently represented at the 4th National Myeloma Workshop.
Read moreThank you to all attendees for contributing to a successful MRDR Interest Group breakfast at Blood 2022!
Read more